Compare LWAY & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LWAY | CBIO |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 389.7M |
| IPO Year | 1987 | N/A |
| Metric | LWAY | CBIO |
|---|---|---|
| Price | $22.11 | $8.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $35.00 | $27.17 |
| AVG Volume (30 Days) | 49.7K | ★ 228.1K |
| Earning Date | 03-13-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $204,069,000.00 | N/A |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $29.61 | ★ N/A |
| Revenue Growth | ★ 12.14 | N/A |
| 52 Week Low | $19.50 | $8.72 |
| 52 Week High | $34.20 | $21.40 |
| Indicator | LWAY | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 30.09 |
| Support Level | $21.25 | $8.99 |
| Resistance Level | $22.50 | $9.69 |
| Average True Range (ATR) | 0.64 | 0.81 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 40.61 | 9.25 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.